Journal Mobile Options
Table of Contents
Vol. 65, No. 5, 2011
Issue release date: May 2011
Eur Neurol 2011;65:302–306

Restless Legs Syndrome in Multiple Sclerosis

Aydar G. · Kurt S. · Karaer Unaldi H. · Erkorkmaz U.
Departments of aNeurology and bBiostatistics, Gaziosmanpasa University Medical Faculty, Tokat, Turkey

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Aims: Multiple sclerosis (MS) is a demyelinating neurodegenerative inflammatory autoimmune disease. Restless legs syndrome (RLS) is characterized as a strong urge to move the legs to stop abnormal sensations there. In this study, we aimed to investigate whether or not the increased RLS frequency seen in MS could be associated with depression and fatigue. Methods: The study involved 98 patients with definite MS and 129 healthy volunteers. The Beck Depression Inventory and Fatigue Severity Scale were used to assess all participants. The patients and the healthy volunteers were examined for RLS according to the criteria of the International Restless Legs Syndrome Study Group. Results: When the factors related to RLS in MS were evaluated, there were significant relationships found among age, type of MS, pyramidal symptoms, intestinal and bladder symptoms, number of lesions in MR, depression, and fatigue. Risk factors for RLS were also seen more frequently in the MS group than in the healthy volunteers. Conclusion: RLS was seen 2.55 times more frequently in patients with MS than in the control group. This was due to the existence of numerous factors rather than a single factor – including depression and fatigue.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Gilroy J: Basic Neurology, ed 3. New York, McGraw-Hill, 2000, pp 199–223.
  2. Confavreux C, Vukusic S, Adeleine P: Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003;126:770–782.
  3. Patten SB, Francis G, Metz LM Lopez-Bresnahan M, Chang P, Curtin F: The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler 2005;11:175–181.
  4. Lublin FD, Miller AE: Multiple sclerosis and other inflammatory demyelinating disease of the central nervous system; in Bradley GW, Daroff BR (eds): Neurology in Clinical Practice, ed 5. New York, Elsevier, 2008, pp 1583–1613.
  5. Kantarcı O, Siva A, Eraksoy M, Karabudak R, Sütlaş N, Ağaoğlu J, et al: Survival and predictors of disability in Turkish MS patients: Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 1998;51:765–772.
  6. Chokroverty S: Sleep and its disorders; in Bradley GW, Daroff BR (eds): Neurology in Clinical Practice, ed 5. New York, Elsevier, 2008, pp 1947–2009.
  7. International Restless Legs Syndrome Study Group: Validation of the International Restless Legs Syndome Study Group Rating Scale for restless legs syndrome. Sleep Med 2003;4:121–132.
  8. Manconi M, Fabbrini M, Bonanni E, Filippi M, Rocca M, Murri L, et al: High prevalence of restless legs syndrome in multiple sclerosis. Eur J Neurol 2007;14:534–539.
  9. Manconi M, Rocca MA, Ferini-Strambi L, Tortorella P, Agosta F, Comi G, et al: Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage. Mult Scler 2008;14:86–93.
  10. Auger C, Montplaisir J, Duquette P: Increased frequency of restless legs syndrome in a French-Canadian population with multiple sclerosis. Neurology 2005;65:1652–1653.
  11. Gomez-Choco MJ, Iranzo A, Blanco Y, Graus F, Santamaria J, Saiz A: Prevalence of restless legs syndrome and REM sleep behavior disorder in multiple sclerosis. Mult Scler 2007;13:805–808.
  12. Italian REMS Study Group: Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep 2008;31:944–952.
  13. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al: Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol 2005;58:840–846.
  14. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.
  15. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561–571.
  16. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD: The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121–1123.
  17. Bakshi R, Shaikh ZA, Miletich RS, Czarnecki D, Dmochowski J, Henschel K, et al: Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 2000;6:181–185.
  18. Hening WA, Allen RP: Restless Legs Syndrome (RLS): the continuing development of diagnostic standards and severity measures. Sleep Med 2003;4:95–97.
  19. Coles A: The curious incident of disability in multiple sclerosis trials. Lancet Neurol 2006;5:899–900.
  20. Moreira NC, Damasceno RS, Medeiros CA, Bruin PF, Teixeira CA, Horta WG, et al: Restless leg syndrome, sleep quality and fatigue in multiple sclerosis patients. Braz J Med Biol Res 2008;41:932–937.
  21. Kasatkin DS, Spirin NN: Possible mechanisms of the formation of chronic fatigue syndrome in the clinical picture of multiple sclerosis. Neurosci Behav Physiol 2007;37:215–219.
  22. Chwastiak LA, Ehde DM: Psychiatric issues in multiple sclerosis. Psychiatr Clin North Am 2007;30:803–817.
  23. Gardener H, Munger KL, Chitnis T, Michels KB, Spiegelman D, Ascherio A: The relationship between handedness and risk of multiple sclerosis. Mult Scler 2009;15:587–592.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50